Literature DB >> 35281976

COVID-19: Non-Invasive Ventilation in Hypoxemic Acute Respiratory Failure.

Fariborz Rezaeitalab1, Fariba Rezaeetalab1, Farzaneh Akbari1, Seyyed Mohammad Ata Sharifi Dalooei1, Soheila Saberi1, Saeedeh S Mirtouni1.   

Abstract

Entities:  

Year:  2022        PMID: 35281976      PMCID: PMC8883681          DOI: 10.4103/ijpvm.IJPVM_512_20

Source DB:  PubMed          Journal:  Int J Prev Med        ISSN: 2008-7802


× No keyword cloud information.
On December 2019, Dr Li Wenliang, an ophthalmologist in Wuhan, China, recognized seven patients with SARS-like illness and warned his colleagues of a possible viral epidemic. He died on February 7, 2020 from the same illness, when it had been identified as coronavirus or COVID-19 and spread throughout the world.[1] A lesson which can be learned from Dr Li's story is that COVID-19 may be first faced by physicians other than pulmonologists or intensive care units staff. The essential way for transmission is from person to person by respiratory droplets. Health care workers, hospitals, and operation rooms potentially are important sources for viral spreading. The reported fatality rate is 2% to 3%, but in older patients it is as high as 8% to 15%. The death rate could escalate at the presence of underlying diseases such as chronic pulmonary disease, diabetes, systemic hypertension, corticosteroid therapy, and other immunosuppressed conditions.[2] The incubation period for COVID-19 has been estimated from 1 to 14 days after exposure, with approximately 4 to 5 days for most cases. The infection has been shown in all ages, including children with the mean age reported between 49 and 56 years.[3] The major clinical presentation of COVID-19 has been fever (88.5%–99%), fatigue (62%–70%), dry cough (59%–68/9%), anorexia (40%), breathlessness to respiratory distress (21.9%–55%), myalgia or fatigue (35.8%), headache (12.1%), diarrhea (4.8%), and nausea and vomiting (3.9%), and also headache, bone pain, myalgia, and anosmia were reported.[2] The most common finding of COVID-19 pneumonia in chest CT scan is bilateral ground glass opacities. In addition, consolidations and nodules were reported. [4] Serum lymphocytopenia, increasing CRP, and LDH were reported. The history, past travelling to endemic areas, contacting with infected patients, was suggestive for detecting of COVID-19. Positive real-time poly chain reaction (RT–PCR) for the virus is the definitive diagnostic test; however, a negative RT–PCR is not a ruled out disease.[5] At this time, we passed minimum 5 peaks of COVID-19 in Iran and 2 peaks in other parts of the world. Nowadays, there is no specific and definitive medication. [6] Effective vaccination against COVID-19 is the most important policy to prevent the spread of the virus and the global pandemic.[7] As the COVID-19 epidemic continued and patients died, researchers applied vaccination prevention.[8] Maintaining tissue oxygenation and preventing cell death are an important principle in approaching patients with respiratory failure of COVID-19 pneumonia. However, the late 1980s non-invasive ventilatory support (NIV) has become a standard treatment in acute exacerbation of COPD (AECOPD) with hypercapnia. Nevertheless, NIV is an important device for COVID-19 with mild and moderate acute respiratory distress syndrome (ARDS) and hypoxemia.[8] The lesson that I learned from the visit of the critically ill patients with COVID-19 in the intensive care unite (ICU) is the application of high levels of positive end expiratory pressure (PEEP) in bilevel positive airway pressure (BiPAP) insertion. High expiratory pressure opens collapsed alveoli and decreases lung stiffness.[9]

Conclusion

As a COVID-19 spreads rapidly, many parts of the public world may be involved. We need to know that Corona virus lives with us, and that it could have deadly outbreaks in society. Hypoxemic respiratory failure is a dramatically presentation of COVID-19 with high mortality. NIV such as BIPAP with high expiratory pressure recommends for these patients.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  9 in total

1.  The Development of COVID-19 Vaccines: Safeguards Needed.

Authors:  Nicole Lurie; Joshua M Sharfstein; Jesse L Goodman
Journal:  JAMA       Date:  2020-08-04       Impact factor: 56.272

2.  Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain.

Authors:  Nicholas Zareifopoulos; Maria Lagadinou; Anastasia Karela; Christina Platanaki; Gerasimos Karantzogiannis; Dimitrios Velissaris
Journal:  Monaldi Arch Chest Dis       Date:  2020-05-05

3.  Intubation and mechanical ventilation of patients with COVID-19: what should we tell them?

Authors:  Nicholas Zareifopoulos; Maria Lagadinou; Anastasia Karela; Gerasimos Karantzogiannis; Dimitrios Velissaris
Journal:  Monaldi Arch Chest Dis       Date:  2020-04-08

4.  Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR.

Authors:  Yicheng Fang; Huangqi Zhang; Jicheng Xie; Minjie Lin; Lingjun Ying; Peipei Pang; Wenbin Ji
Journal:  Radiology       Date:  2020-02-19       Impact factor: 11.105

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  Ophthalmologists Are More Than Eye Doctors-In Memoriam Li Wenliang.

Authors:  Richard K Parrish; Michael W Stewart; Sarah L Duncan Powers
Journal:  Am J Ophthalmol       Date:  2020-03-09       Impact factor: 5.258

7.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

8.  Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.

Authors:  Heshui Shi; Xiaoyu Han; Nanchuan Jiang; Yukun Cao; Osamah Alwalid; Jin Gu; Yanqing Fan; Chuansheng Zheng
Journal:  Lancet Infect Dis       Date:  2020-02-24       Impact factor: 25.071

Review 9.  Viral targets for vaccines against COVID-19.

Authors:  Lianpan Dai; George F Gao
Journal:  Nat Rev Immunol       Date:  2020-12-18       Impact factor: 53.106

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.